Summary Plasminogen activator (PA) is a serine protease which exists in two forms: tissue-type (t-PA) and urokinase-type (u-PA). The activity (<60 unitmg-' vs >,60 unitmg-' protein) was found to be a significant prognostic factor for disease-free and overall survival of about the same import as lymph node involvement. Furthermore, the combination of total PA activity and nodal status could be even more precise in predicting survival times and probabilities in individual patients. This retrospective study demonstrates the total PA activity is a valuable prognostic factor in determining prognosis in human breast cancer.
Neoplastic cells are known to express various proteolytic enzymes, which, in animal models, make them invasive and favour their dissemination to distant sites (Orenstein et al., 1983; Persky et al., 1986; Mignatti et al., 1986; Butler et al., 1986; Reich et al., 1988) . Plasminogen activator (PA) is such a serine protease. Two main forms of PA are known: tissuetype (t-PA) and urokinase-type (u-PA) (Blasi, 1988) . A number of investigators have suggested that a high activity of this enzyme in a tumour may destroy peritumoural tissues (Dano et al., 1985; Colombi et al., 1986) . Plasmin degrades proteins of the extracellular tumour stroma and of the basement membrane (fibrin, fibronectin, laminin) (Duffy, 1987; Reich et al., 1988 ) and activates procollagenase IV, which degrades collagen (Paranjpe et al., 1980) . This tumourassociated proteolysis provides the basis for tumour cell invasion and facilitates the release and subsequent metastasis of tumour cells.
We showed previously that in 7,12-dimethylbenz(a)anthracene (DMBA)-induced rat mammary carcinomas and in the human breast cancer cell line, MCF-7, the total PA activity of PAs is regulated by oestrogen at a transcriptional level via an oestrogen receptor system, and pointed out that the total PA activity may be a useful marker of oestrogen action in breast cancer cells (Yamashita et al., 1984; Inada et al., 1991; Inada et al., 1992) . Furthermore, we have measured total PA activity in tissue extracts from human breast cancer and found that the activity correlates positively with oestrogen receptor (ER) status (Yamashita et al., 1986) . We have now extended this study and reviewed retrospectively the medical records of these patients. We show here that patients with breast cancers containing low levels of total PA activity, unexpectedly, have significantly shorter disease-free and overall survival times.
Materials and methods

Patients
The 235 breast cancer patients analysed in this were the same analysed in a previous study (Yamashita et al., 1986) in which the total PA activity in breast cancer tissues was determined. These patients underwent curative mastectomy in the Department of Surgery II, Kumamoto University Hospital, during the 4-year period from 1981 to 1984. The medical records of these 235 patients were evaluated retrospectively in this study. The median follow-up period for patients with a low PA activity was 8.5 years (range, 7.1-10.3 years) and for patients with intermediate or high levels it was 8.5 years (range, 7.0-10.5 years). Every death in this study was due to metastatic breast cancer.
The clinicopathologic parameters studied for prognostic value were age, menstrual status, tumour size, number of positive nodes, histologic type, histologic grade, vessel involvement, ER, Progesterone receptor (PgR) and total PA activity. Tumour size was measured as the greatest diameter of the tumour. The extent of lymph node metastasis was categorised into one of three groups: 0, 1 to 3 and 4 +. Each tumour was typed according to the classification of the Japan Mammary Cancer Society (9th edition, 1988) and was graded in parallel according to the criteria described by Bloom and Richardson (1957) . In this series, 228 of the tumours were invasive ductal carcinomas and seven were non-invasive ductal carcinomas. Every histological analysis was made by the same author (J.Y.).
Assay for total PA activity Frozen tissue was homogenised and extracted with 50 mM Tris-HCI buffer (pH 7.4) containing 0.25% Triton X-100, as described previously (Yamashita et al., 1984) . Total PA activity was determined as described previously (Yamashita et al., 1984) in a coupled assay using S-2251 (H-D-Val-LeuLys-pNA, Kabi, Stockholm) as a substrate for plasmin. Total PA activity determined in this study represented a mixutre of t-PA and u-PA activities.
Assay for hormone receptors ER and PgR were determined by the dextran-coated charcoal method as described previously (McGuire et al., 1977) . Tumour specimens were considered hormone receptorpositive if they contained at least 10 fmol specific binding sites mg-' protein.
Statistical analyses
The BMDP Statistical Package (BMDP Statistical Software, Inc., Los Angeles, CA.) program (Dixon, 1985) for the computer (IBM 4381; IBM, New York) was used for all analyses. The BMDP P4F program was used to perform the chi-square test to compare the data among groups of patients. Analyses of disease-free and overall survival were performed using the Kaplan-Meier method (Kaplan & Meier, 1958) in the BMDP PIL program. Tests of differences between curves were made with the log-rank test (Mantel, 1966) for censored survival data. The BMDP P2L program was used for Cox analysis (Cox, 1972) of positive nodes, histologic type, histologic grade or vessel involvement. Only the ER and PgR positivity were associated with a high level of PA activity (P = 0.05, P = 0.01, respectively). This was not surprising, since total PA activity is increased by oestrogen in breast cancer cells and this result is consistent with our previous reports (Yamashita et al., 1986) .
While total PA activity does not appear to correlate significantly with most known prognostic factors, disease-free and overall survival are observed to differ according to the PA activity status in primary breast cancer tissues. As shown in Figure 1 , patients with breast cancer tissue containing a low level of PA activity had a significantly shorter diseasefree survival (P = 0.005) and overall survival (P = 0.018) time than patients with a high or intermediate level of enzyme activity. With respect to the proportion receiving adjuvant endocrine therapy or adjuvant chemotherapy, there was no significant difference among three groups of patients (Table  II ). The three groups of patients had similar adjuvant therapies during the first 2 years after their operation. Table  III For the reason that low PA activity ( <60 unit mg-' protein) was associated with a significantly poor prognosis in disease-free and overall survival times, the remaining analyses were performed using a cut-off point of 60 unit PA activitymg'1 protein. (Table V) , PA activity was a significant predictor of recurrence and death which was independent of the other three factors. In the multivariate analysis, neither tumour size nor histologic grade were related significantly to disease recurrence or death.
The independence and the additional importance of total PA activity as a prognostic factor relative to lymph node status are also illustrated in Figure 2 , where low PA activity identified subgroups with poorer disease-free and overall survival among both lymph node-negative and lymph nodepositive groups of patients (P = 0.04 in both lymph node involvement categories).
Discussion
The present study offers statistical evidence that total PA activity in primary breast cancer tissues is a useful prognostic marker which identifies clearly high and low risk patients. A subgroup of patients with a high risk for recurrence was identified in node negative cancer patients which are usually considered to have a good prognosis. On the other hand, in node positive patients considered to be at high risk for recurrence, a subgroup was identified which had a more benign outcome.
There are two types of PAs: the urokinase type (u-PA) and the tissue-type (t-PA). While both catalyse cleavage of the peptide bond between Arg-Val in plasminogen, thus converting the proenzyme to plasmin, they differ in many aspects of their molecular weight, immunological reactivity and amino acid sequence (Blasi, 1988 that antibodies against u-PA, but not those against t-PA, inhibit cancer cell invasion and metastasis after transplantation of Hep-3 tumour cells into chicken embryos. This suggests also that u-PA is important in tumour cell invasion and metastasis. Furthermore, several enzymatic and immunometric assays performed on human tissues have demonstrated high u-PA (but not t-PA) activity in malignant tumours, when compared to their non-neoplastic counterparts, suggesting that u-PA is the dominant in cancer and that t-PA is unlikely to play a role in cancer spread (Evers et al., 1982; Sappino et al., 1987) . Several reports (Duffy et al., 1988a; Janicke et al., 1989; Duffy et al., 1990; Janicke et al., 1990) have suggested that patients with high level of u-PA antigen or activity have a significantly shorter disease-free survival and that u-PA could be used as a new prognostic marker in human breast cancer. Duffy et al. (1988a; 1988b; reported that in breast cancer u-PA correlates with poor prognosis in breast cancer and t-PA correlates with good prognosis, and that measurement of total PA activity, therefore, has no prognostic value. In this regard, our results are inconsistent with the finding of Duffy et al. (1988b) that total PA activity can not be a prognostic marker in breast cancer. The differences in these results may be accounted for partly by differences in the follow-up period for patients. The median follow-up period for patients in our study (8.5 years) was much longer than that in the cited studies in which the median follow-up period was 19 months (Duffy et al., 1988a) , 35 months , 12.5 months (Janicke et al., 1989; Janicke et al., 1990) , or 26 months (Duffy et al., 1988b) . In our study, there is not statistically significant difference at up to 22 months both in disease-free survival and overall survival.
Our results show that a high total PA activity in primary breast cancer tissue indicates a good prognosis. This may be related to the fact that t-PA is an estrogen-inducible enzyme and that is present when the total PA activity is high (Dickermann et al., 1989; Mizoguchi et al., 1990; Uchiumi et al., 1991; Yamashita et al., 1992) . The presence of the ER itself in breast cancer is generally thought to be associated with a good prognosis (Foekens et al., 1989) , although in our study the prognostic value of ER (P = 0.075) and PgR (P = 0.06) only approached significance (Table IV) . Thus, the utility of total PA as a marker for good prognosis in breast cancer may be related to the fact that t-PA is estrogeninducible and thus reflects an intact ER system. Until now, we have determined t-PA and u-PA activities in 144 human breast cancer specimens using the monoclonal antibodies to human t-PA and u-PA and showed a greater proportion of total PA activity is composed of t-PA (84.5-96.3%) (unpublished data). The fact that our assay for total PA activity is biased towards t-PA may support above assumption.
Treatment is an important confounding factor. Although the three groups of patients studied had similar adjuvant therapies (Table II) Reilly et al. (1990) have reported that high levels of not only u-PA antigen but also high levels of plasminogen activator inhibitor-I (PAI-1) antigen, a fast and specific inhibitor of PAs, were found in the majority of breast cancer tissues and that the levels of both antigens correlate positively with progression in breast cancer. Of interest was finding that a significant positive correlation exists between u-PA and PAI-1 antigen levels and signs of progression of breast cancer, such as lymph node involvement. Although the mechanism by which u-PA and its inhibitor, PAI-1, are co-expressed in aggressive breast cancer is not known, these results raise the possibility that the low total PA activity in breast cancer with poor prognosis might be due to coexpression of u-PA and PAI-I and to the lack of estrogeninducible t-PA. As our assay is biased towards t-PA, when total PA is high t-PA is high. In breast cancer tissues containing high t-PA activity, PAI-i might not be sufficient to inhibit abundant t-PA activity.
In conclusion, it is obviously necessary to evaluate tissuetype and urokinase-type components of total PA activity and to examine PAI-i levels in our series which may clear up the unexpected results in this report. However, this is the first report showing that patients with low total PA activity have a poorer prognosis than do those with high PA activity and that total PA activity is a significant prognostic factor in patients with breast cancer. After surgery, breast cancer patients with low tumour PA activity should be followed carefully in case effective pharmacotherapy becomes available.
